Russell Investments Group
SNDX icon

Russell Investments Group’s Syndax Pharmaceuticals SNDX Stock Holding History

Russell Investments Group’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.95M Buy
135,012
+33,520
+33% +$697K ﹤0.01% 1856
2026
Q1 		$2.37M Buy
101,492
+11,853
+13% +$258K ﹤0.01% 1786
2025
Q4 		$1.88M Buy
89,639
+10,101
+13% +$176K ﹤0.01% 1898
2025
Q3 		$1.22M Sell
79,538
-46,620
-37% -$610K ﹤0.01% 2115
2025
Q2 		$1.18M Buy
126,158
+8,545
+7% +$94.1K ﹤0.01% 1981
2025
Q1 		$1.44M Buy
117,613
+88,591
+305% +$1.25M ﹤0.01% 1870
2024
Q4 		$384K Buy
29,022
+15,508
+115% +$265K ﹤0.01% 2367
2024
Q3 		$260K Buy
13,514
+231
+2% +$4.77K ﹤0.01% 2454
2024
Q2 		$273K Buy
13,283
+2,871
+28% +$60.1K ﹤0.01% 2393
2024
Q1 		$248K Sell
10,412
-6,674
-39% -$149K ﹤0.01% 2393
2023
Q4 		$369K Sell
17,086
-1,712
-9% -$26.3K ﹤0.01% 2307
2023
Q3 		$273K Buy
18,798
+10,298
+121% +$195K ﹤0.01% 2420
2023
Q2 		$178K Buy
+8,500
New +$177K ﹤0.01% 2491
2023
Q1 		– Sell
-39,595
Closed -$1.01M – 3378
2022
Q4 		$1.01M Buy
+39,595
New +$924K ﹤0.01% 1969
2021
Q3 		– Sell
-1,515
Closed -$26K – 3202
2021
Q2 		$26K Sell
1,515
-62,587
-98% -$1.15M ﹤0.01% 3170
2021
Q1 		$1.43M Sell
64,102
-42,687
-40% -$964K ﹤0.01% 2069
2020
Q4 		$2.38M Sell
106,789
-18,247
-15% -$378K ﹤0.01% 1663
2020
Q3 		$1.84M Buy
125,036
+20,914
+20% +$319K ﹤0.01% 1738
2020
Q2 		$1.54M Sell
104,122
-30,327
-23% -$462K ﹤0.01% 1794
2020
Q1 		$1.47M Buy
+134,449
New +$1.26M ﹤0.01% 1634
2019
Q1 		– Sell
-2,000
Closed -$9K – 3004
2018
Q4 		$9K Sell
2,000
-1,900
-49% -$10.4K ﹤0.01% 2893
2018
Q3 		$32K Sell
3,900
-100
-3% -$713 ﹤0.01% 2883
2018
Q2 		$28K Buy
+4,000
New +$39.2K ﹤0.01% 2863

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Russell Investments Group's SNDX Position: Q2 2026 in Review

Russell Investments Group increased its Syndax Pharmaceuticals (SNDX) stake by 33% in Q2 2026, buying an estimated $697K and bringing the position to 135,012 shares worth $2.95M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

Russell Investments Group first reported a position in SNDX in Q2 2018 and has held it in 23 quarters since. 73 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Russell Investments Group held 135,012 shares of Syndax Pharmaceuticals worth $2.95M as of Q2 2026.
  • Russell Investments Group bought 33,520 Syndax Pharmaceuticals shares in Q2 2026, an estimated $697K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #1856 holding.
  • Russell Investments Group first reported a position in Syndax Pharmaceuticals in Q2 2018 and has held it in 23 quarters since.
  • 73 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.